Key Takeaways
- FDA has authorized Corcept’s Lifyorli (relacorilant) for treating platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer
- Shares of CORT rocketed approximately 40% following Wednesday’s announcement
- The regulatory review concluded 2.5 months before the target date
- Trial results demonstrated median overall survival of 16 months compared to 11.9 months with standard treatment
- The company holds a market capitalization near $3.97 billion with analysts targeting $66.80 per share
Corcept Therapeutics received regulatory clearance Wednesday for its cancer treatment relacorilant, marketed as Lifyorli. The authorization covers use alongside nab-paclitaxel for adult patients diagnosed with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Corcept Therapeutics Incorporated, CORT
Shares experienced a roughly 40% surge following the announcement — marking one of the most significant single-session gains in the biotech sector this year.
The approval applies specifically to individuals who have undergone one to three previous systemic treatment courses, with at least one involving bevacizumab. While targeted, this represents a substantial patient group within a challenging-to-treat cancer category.
Regulators wrapped up their evaluation 2.5 months before the scheduled target date. Such accelerated completions are uncommon and indicate the agency identified compelling evidence in the clinical data.
Clinical Trial Outcomes
The authorization stems from results of the ROSELLA clinical study — a multi-site investigation involving 381 participants. One group received the relacorilant-nab-paclitaxel combination, while the control group received nab-paclitaxel as a monotherapy.
Patients on the combination regimen achieved a median progression-free survival of 6.5 months compared to 5.5 months for those on the single agent. Overall survival reached 16 months with the combination therapy versus 11.9 months for nab-paclitaxel alone.
While the improvements may appear incremental, they represent meaningful progress in a clinical scenario with few effective alternatives. Platinum-resistant ovarian cancer presents substantial treatment challenges, making any survival benefit noteworthy.
Relacorilant functions as a glucocorticoid receptor antagonist. The recommended dosing schedule is 150 mg administered orally once daily for three consecutive days surrounding each nab-paclitaxel infusion.
Nab-paclitaxel is administered at 80 mg/m² intravenously on days 1, 8, and 15 within each 28-day treatment cycle.
Safety Profile and Adverse Events
The drug’s labeling carries contraindications for individuals requiring corticosteroids for critical medical conditions. Frequently reported adverse effects include reduced hemoglobin and neutrophil counts, fatigue, nausea, diarrhea, thrombocytopenia, rash, and appetite loss.
Examining the company’s financial performance reveals a nuanced picture. Revenue has expanded 22.3% across the previous three years. Net profit margin stands at 13.09% while gross margin reaches an impressive 98.3%.
Earnings growth, however, declined 33.3% year-over-year. The price-to-earnings multiple sits at 45.49, positioning it toward the elevated range.
The company’s balance sheet appears robust — featuring a current ratio of 2.92 and minimal debt-to-equity ratio of 0.01.
Institutional investors control 72.18% of outstanding shares. The consensus analyst price target of $66.80 implies additional upside potential beyond Wednesday’s substantial rally.
Corcept’s Altman Z-Score of 14.14 reflects strong financial health. The Beneish M-Score of -2.81 indicates low probability of financial statement manipulation.
Prior to Wednesday’s session, the 50-day moving average registered at $37.32, while the RSI reading of 41.26 showed the stock was not in overbought territory before the surge.
The post Corcept Therapeutics (CORT) Stock Rockets 40% as FDA Greenlights Lifyorli Cancer Treatment appeared first on Blockonomi.